科学家“修补受损心脏”
Scientists 'mend broken hearts'
329字
2019-12-18 20:42
76阅读
火星译客

Injecting proteins similar to insulin directly into the heart can cause damaged cells to repair themselves and begin regenerating again, researchers said.

研究人员说,像类似于胰岛素那样把蛋白直接注入心脏,可使受损细胞得到修复并重新再生。

Tests on pigs showed that the dormant cells could begin regrowth following a "regenerative medicine" treatment using certain growth factors – naturally occurring proteins which cells use to communicate with their environment.

对猪进行的试验表明,应用“药物再生”医疗技术可让沉睡细胞重新生长。它是采用某种生长素---天然蛋白激活细胞与外部沟通。

Experts from Liverpool John Moores University (LJMU) said the four-year study presented a "significantly different" therapy to those currently being developed by scientists.

英国利物浦约翰莫尔大学(LJMU)专家说,该项历经四年研究取得的成果,“明显不同于”当前科学家提出的治疗手段。

The findings, produced with teams from Italy and Spain, could lead to simple and affordable treatments for heart attacks, they said.

他们说,该项研究是与意大利和西班牙研究团队共同合作完成的。该项研究为心脏病治疗带来简单易行的创新医治方法。

Dr Bernardo Nadal-Ginard, Director of LJMU Stem Cell & Regenerative Biology Unit, said approaches currently being pursued in clinical trials were "time consuming" and "expensive".

英国利物浦约翰莫尔大学干细胞与再生生物学系主任Bernardo Nadal-Ginard博士认为,目前门诊采用的医疗方法是“费时”、“费钱”的。

He said: "It is unlikely that they will have a major impact on the treatment of life-threatening diseases affecting millions of people, such as heart disease and failure.

他说:“那些方法对威胁众多人们生命的疾病(诸如心脏病和心力衰竭)的治疗不可能取得很大效果。

"In contrast, this new approach by LJMU could ultimately lead to a clinical myocardial regenerative therapy which is effective, simple, affordable, readily and widely available and easy to apply and compatible with the current clinical standard of cardiac care."

 “与其相反,利物浦约翰莫尔大学提出新方法完全能应用在门诊治疗中,实现心肌再生治疗。它是一种简单、有效、易于应用、便于广泛推广的方法,与现行门诊心脏保健规范相符。”

Dr Nadal-Ginard said the research shows that injecting growth factors IGF-1 and HGF caused significant "anatomical, histological and physiological" regeneration of damaged hearts and "sets the path" for testing clinical trials.

Nadal-Ginard博士说:研究显示,注射生长素IGF-1和 HGF对受损心脏会有“解剖学、组织学和生理学”上重大再生作用,它为门诊医疗技术“开辟了新道路”。

Another member of the LJMU BioStem research team, Dr Georgina May Ellison, said funding had been secured for clinical tests of the new method to begin at the Vall d'Hebron University Hospital in Barcelona.

英国利物浦约翰·莫尔大学生物干细胞研究团队另一成员Georgina May Ellison博士说:“该研究将在西班牙巴塞罗纳的瓦尔德希伯伦大学医院投入门诊医疗,已经获得资金资助。”

She said: "We have obtained very encouraging evidence from this the preclinical data.

她说:“我们在已取得了充分的临床前试验数据,这为取得成功提供了保证。

"If we can get funding we would want to run clinical tests the UK. We are in talks with funding bodies and the Liverpool Heart and Chest Hospital to do those clinical tests there."

“若资金到位,我们还将在英国开展门诊医疗试验。现正在与提供资助的单位和英国利物浦心胸医院商谈合作事宜。”

"I think it holds-out the highest promise that we have on cellular therapy that is out there at the moment."

“我想这是最好的承诺,届时就可开始细胞医疗了。”

0 条评论
评论不能为空